icon3

Liquid Biopsy Market By Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Others) By Applications (Lung, Colorectal, Liver, Others) Regional Analysis & Forecast – 2024

  • OI-63
  • |
  • Published date: Jan, 2019
  • |
  • In Vitro Diagnostics
  • |
  • Pages

Introduction:



  • A liquid biopsy is testing of a sample of blood of tumor circulating within blood or pieces of DNA of the tumor to detect cancer cells. Multiple blood samples are taken over the period to understand changes in molecular structure. It accurately detects genetic mutation to verify the existence of cancer such as lung cancer, gastrointestinal, leukemia, lymphoma, and breast cancers. The test detects these molecules or cells in various bodily fluids, including blood, urine, cerebrospinal fluid, or saliva.


Market overview:



  • Global Liquid biopsy market was valued at $.... million in 2018 and is estimated to reach at $... million by 2025, registering a CAGR of ….% from 2018 to 2025. The global liquid biopsy market is segmented based on circulating biomarker, product, circulating biomarker, cancer type, end user, and geography. Rising applications of liquid biopsy and personalized medicine to spur the use of liquid biopsy tests in clinical practice and Increase in aging population, cancer Incidences drives liquid biopsy market.


Market Drivers:



  • Cancer Monitoring: Adoption of Liquid Biopsy avoids repeat or unwanted biopsies

  • Early Cancer Screening Market: Pre-cancer screening and early detection serve as long-term growth drivers for liquid biopsy.

  • New liquid biopsy product launches to fuel market revenues.

  • Increasing focus of manufacturers on research & development through collaborations to bolster the growth of liquid biopsy market.


Market Restraints:



  • Gold Standard Inhibiting Growth: Tissue based testing and imaging remains the gold standard of care.

  • High Cost of Technology: Several liquid biopsy assays are based on high-throughput NGS technologies. The high cost of these technologies inhibits liquid biopsy uptake to some extent.

  • Clinical Sensitivity: Clinical sensitivity presents a challenge to liquid biopsy because ctDNA is rare compared to hematological molecules found in a blood sample.

  • Reimbursement Challenges: Liquid biopsy market is unregulated in most countries, where most tests are offered as laboratory developed tests (LDTs) with a self-pay option.


Segmentation:


Global Liquid Biopsy market is segmented based on application type: Breast, Lung, Colorectal, Liver, Prostate, and Others


Circulating Biomarker: Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA


Product: Assay kits, Instruments, Services


Geography: North America, Europe, APAC      


End User: Hospitals, Laboratories


Segmentation Analysis:


Application Analysis:  Three key applications of liquid biopsy can be a therapy selection tool for metastatic breast cancers, therapy selection for other metastatic cancers, and molecular health monitoring. With the rising incidence of metastatic cancer across the globe, the therapy selection tool for metastatic breast cancers segment is poised to hold a considerable share in the market throughout the forecast period


Biomarker Type analysis: The liquid biopsy market has been divided into circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and exosomes (Macrovesicles with Protein, RNA, DNA). There are about 8-10 liquid biopsy tests based on CTCs and ctDNA that are currently commercialized. Furthermore, over 30 tests based on all three of these biomarkers are in clinical development. Commercialization of these tests in the offing is estimated to benefit the growth of the overall market.


Regional analysis: North America accounted for the largest share of the global liquid biopsy market in 2018, followed by the Asia Pacific. In North America, the United States accounted for the largest share of the liquid biopsy market. In Europe, Germany and France are the leading markets for liquid biopsy. Asia pacific is likely to be the fastest growing market for liquid biopsy during the forecasting period. In Asia Pacific, Japan and China are the leading markets for liquid biopsy. Latin America is the fourth largest market for liquid biopsy, being followed by Middle East & Africa.


End User analysis: In 2018, Reference laboratories captured the largest share of the global liquid biopsy market. Hospital and Physician laboratories occupied the second highest share of the liquid biopsy market in 2018, being followed by Academic and Research Centers


Key Opportunities:


Presently, R&D on cancer diagnosis is primarily focused toward liquid biopsy. Market players and research institutes are conducting extensive clinical trials to develop a highly sensitive liquid biopsy platform. In May 2018, Grail, a U.S.-based biotechnology company, raised US$ 1 Bn in VC funding and embarked on a 120,000-patient study for early breast cancer detection.


In January 2018, researchers at Johns Hopkins developed a test called CancerSEEK, which is a non-invasive multianalyte test that analyzes levels of eight cancer proteins and presence of cancer gene mutation in circulating DNA in the blood. The test included more than 1000 patients with nonmetastatic, stages I to III cancers of the ovary, stomach, liver, pancreas, esophagus, lungs, colorectum, and breast. Extensive research on liquid biopsy aimed at promoting early diagnosis in cancer is likely to drive the market for during the forecast period


There are around 8-10 fluid biopsy tests on the basis of CTCs and ctDNA that are as of now commercialized. Moreover, more than 30 tests in view of each of the three of these biomarkers are in clinical improvement by some major market players.

Report Description: The report covers in-depth analysis on Liquid biopsy Assays currently in development. The report assesses the pipeline Liquid biopsy Assays by stage of development (early development, pre-clinical, Clinical and In Approval), by application (Breast, Lung, Liver, Colorectal, Prostate and others. In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement patent, and regulatory designations.


The report includes in-depth company profiles of key players in Liquid Biopsy Assays market. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.


The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.

Image result for liquid biopsy


 


 

Our research works on a holistic 360° approach to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involve the following steps:




  • Data Collation (Primary & Secondary)




  • In-house Estimation (Based on proprietary databases and Models)




  • Market Triangulation




  • Forecasting




  • Market-related information is assembled from both primary and secondary sources. 






  • Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services. 






  • Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others. 






  • Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. 





 


REPORT YOU MIGHT BE INTERESTED

Choose Licence Type

$3,850.00
$4,950.00


(For Corporate Licence Only) Complementary
Credit card Logo
Inquiry Before Buying

Related Reports


Contact Us

Email Us at: sales@optimainsights.org | Reach Us at: +91 966 6620 365 | +1 424 2554 365 (US)